Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,916,345.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $517.51, for a total value of $4,916,345.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $167,902,496.93. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Price Performance

UTHR opened at $492.02 on Thursday. United Therapeutics Corporation has a one year low of $375.61 and a one year high of $609.35. The business has a 50 day simple moving average of $528.12 and a two-hundred day simple moving average of $539.79. The firm has a market capitalization of $21.10 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 2.56 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company earned $6.41 EPS. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Toth Financial Advisory Corp lifted its position in United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. Fiduciary Financial Advisors bought a new stake in shares of United Therapeutics in the 2nd quarter worth $30,000. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at $31,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.